American Pharmaceutical Partners ( APPX) doesn't expect to get approval for Ceftriaxone for injection in the near term, citing information the drug company received this week from a raw material supplier that was inspected by the Food and Drug Administration.

The company said the development doesn't affect any currently marketed products, and American Pharmaceutical said its previous guidance of 8% to 10% annual growth in its core generic injectable business remains unchanged.

Shareholders were concerned however, sending American Pharmaceutical down $4.85, or 11%, to $40.70 in extended trading.

American Pharmaceutical, of Schaumburg, Ill., develops and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets.

More from Stocks

Has Wall Street Completely Lost Its Mind on General Electric?

Has Wall Street Completely Lost Its Mind on General Electric?

Tesla CEO Elon Musk Is Cracking Under Immense Stress and Investors Should Worry

Tesla CEO Elon Musk Is Cracking Under Immense Stress and Investors Should Worry

10 Questions for PayPal Ahead of Its Big Investor Day

10 Questions for PayPal Ahead of Its Big Investor Day

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

High-Flying Mutual Funds Begin to Favor Energy but Tech Still Reigns Supreme

High-Flying Mutual Funds Begin to Favor Energy but Tech Still Reigns Supreme